STAT

•

Csatorna • 2 műsor

Üzlet

Üzlet

Hetente frissül
Hírek

Hírek

Kéthetente frissül

JAN. 14.

384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen

For this very special episode of The Readout LOUD Allison, Adam, and Elaine are live from the J.P. Morgan Healthcare Conference in San Francisco. The hosts are joined by ARCH Venture Partners co-founder and managing director Bob Nelsen and new Novo Nordisk CEO Mike Doustdar joins the podcast hosts live to discuss his first few months on the job and the company's push to regain market share in the competitive obesity market.

jan. 14.

•

1 ó 8 p
2025. 12. 17.

Francis Collins and Marc Siegel say medicine is a gift from God

Religion and science can often seem in opposition, at least culturally. But they don’t have to be, say Marc Siegel and Francis Collins. Siegel, who is a physician and a senior medical analyst at Fox News, has recently published a new book, “The Miracles Among Us: How God's Grace Plays a Role in Healing,” in which he tells stories of unexpected — miraculous, he says —recoveries. On this episode of the “First Opinion Podcast,” host Torie Bosch speaks with Siegel and Francis Collins — former director of the National Institutes of Health and the author of “The Language of God: A Scientist Presents Evidence for Belief.” They discuss the intersection of faith and science, particularly the ways that some Christian communities have increasingly become skeptical of medicine like vaccines.

2025. 12. 17.

•

42 perc
2025. 11. 20.

379: How Mark Cuban plans to ‘f— up’ health care

How much time does Mark Cuban spend thinking about health care? Why does he think TrumpRx, a direct drug purchasing platform that the Trump administration aims to launch, is “the most incredible program ever”? And what are his thoughts on sports betting? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Cuban comes on for an extensive chat about the latest biosimilar launch by his company, Cost Plus Drugs, as well his broader thoughts on the drug industry and how the direct-to-consumer field is changing.We also chat about the news this week, including more M&A deals and an upcoming Alzheimer’s readout from Novo Nordisk.

2025. 11. 20.

•

37 perc
2025. 12. 04.

380: A new top drug regulator and the future of psychedelics

On this week’s episode of "The Readout Loud": a look at an emerging class of psychedelic drugs that may treat depression, anxiety, and other psychiatric conditions without the hallucinogenic “trip.” Plus, a dash through the week’s biotech news. Our special guest this week is David Olson, director of the UC Davis Institute for Psychedelics and Neurotherapeutics and the co-founder of Delix Therapeutics, a startup that is developing a new class of neuropsychiatric medicines that are similar to psychedelics in that they can exert strong and rapid therapeutic benefits, but without the hallucinogenic effects.

2025. 12. 04.

•

33 perc
2025. 10. 30.

376: BridgeBio’s great week and Moderna’s unraveling

Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween? We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on BridgeBio CEO Neil Kumar to discuss the company’s positive Phase 3 readouts and our colleague Jason Mast to discuss Moderna’s struggles following its Covid-19 vaccine boom.

2025. 10. 30.

•

38 perc
2025. 12. 18.

382: Biotech's year in review

Is the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays? We discuss all that and more on this week's episode of "The Readout LOUD," the last episode of the year. We bring on Bruce Booth, partner at venture capital firm Atlas Venture, to reflect on everything that's happened in the biotech industry this year and to look ahead at the trends next year.We also chat about Adam's picks for best and worst biopharma CEOs in 2025, and why Eli Lilly and Novo Nordisk's direct-to-consumer offerings may be contributing to employers' decisions to drop coverage of weight loss drugs.

2025. 12. 18.

•

34 perc
2025. 12. 10.

The revolution in dementia care is just beginning

When Jason Karlawish started working with dementia patients in the late ’90s, there often wasn’t much he could offer them. “I gave them a diagnosis,” he told me on this week’s episode of the “First Opinion Podcast,” but had limited medications to prescribe. Now Karlawish — who is STAT’s Neurotransmissions columnist; a professor of medicine, medical ethics, health policy, and neurology at the University of Pennsylvania; co-director of the Penn Memory Center; and executive producer of the “Age of Aging” podcast — says a revolution is taking place in dementia care, thanks to diagnostics that are removing uncertainty and treatments that actually have some effect.

2025. 12. 10.

•

40 perc
2025. 02. 06.

340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing. We also talk about the advancement of RFK Jr.'s nomination to be HHS secretary, the latest pharma earnings, and the approval of a non-opioid pain drug from Vertex Pharmaceuticals.

2025. 02. 06.

•

35 perc
2024. 10. 02.

108: How the 2024 election gets mental health right — and wrong

Every four years, someone says “This is the most important election ever.” But it’s hard to question the long-term impact Election Day 2024 will have — from the top of the ballot on down. So the first five episodes of the fall 2024 season of the “First Opinion Podcast” will grapple with the campaign and its intersection with health, medicine, and the life sciences. I’ll speak with experts on issues that have come up on the campaign trail, topics that candidates should focus on, and what a second Trump or first Harris administration might hold. Think of it as “First Opinion Podcast Hits the Trail,” perhaps, except I’m staying home in the swing state of Pennsylvania fending off campaign texts. For the debut episode, I spoke with Kathleen Kelly Daughety, vice president of campaigns and civic engagement for Inseparable, a mental health advocacy organization with a strong focus on policy.

2024. 10. 02.

•

34 perc
2024. 11. 21.

332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

Atlas Venture Partner Bruce Booth joins the podcast to discuss his annual year in review report, the influence of China, and what the new Trump administration might mean for innovation. Adam and Allison also recap the latest news in the life sciences, including a new science chief at Pfizer, a new job for Ned Sharpless, and the ongoing presidential appointments.

2024. 11. 21.

•

35 perc

Voices from the frontiers of health and medicine